Almost everything in the brain flows forward, from presynaptic sender to postsynaptic receiver. The endocannabinoid system breaks this rule. Endocannabinoids are made by the receiving neuron and flow backward across the synapse to bind receptors on the sending neuron. This is retrograde signaling, and it is uniquely informative as a regulatory architecture.
Here is the sequence. A postsynaptic neuron has been receiving a strong barrage of input. Intracellular calcium rises. Membrane lipid precursors in the postsynaptic cell are enzymatically converted to anandamide or 2-arachidonoylglycerol (2-AG), the two main endocannabinoids. These molecules diffuse backward across the synaptic cleft and bind CB1 receptors on the presynaptic terminal of the neurons that were firing onto it. CB1 activation suppresses further neurotransmitter release.
Functionally, this is a feedback brake. The postsynaptic neuron, when overwhelmed, sends back a chemical message saying enough — slow down. The presynaptic neuron complies, reducing its release until the postsynaptic activity calms.
Two features make this system pharmacologically important. First, CB1 receptors are densely expressed throughout the brain — in cortex, hippocampus, amygdala, basal ganglia, cerebellum, and hypothalamus. They are one of the most abundant G-protein-coupled receptors in the central nervous system. Second, CB1 receptors regulate release of almost every neurotransmitter — glutamate, GABA, acetylcholine, dopamine, serotonin, norepinephrine. The endocannabinoid system is positioned to modulate signaling almost everywhere.
This is why cannabis use disrupts so many circuits at once. THC, the primary psychoactive compound in cannabis, is a partial CB1 agonist. By activating CB1 receptors broadly, THC perturbs a regulatory system that touches almost every synapse. The clinical effects are diffuse: altered perception, memory impairment, anxiety or relaxation (depending on dose and individual), appetite stimulation, motor effects, time perception changes, social effects. There is no single mechanism to point to because there is no single mechanism — the substance has been dropped into the master volume knob of the brain.
Therapeutically, the endocannabinoid system is increasingly targeted. Cannabidiol (CBD), which acts partly through CB1, partly through inhibition of anandamide breakdown, and partly through non-cannabinoid receptors, is FDA-approved for specific pediatric epilepsies (Dravet syndrome, Lennox-Gastaut syndrome). Dronabinol and nabilone, synthetic THC analogs, are used for chemotherapy-induced nausea. Research is ongoing for chronic pain, PTSD, multiple sclerosis spasticity, and other indications.
Clinically, the most important point about the endocannabinoid system in adolescent psychiatry is that cannabis use during the developmental window — particularly heavy use — appears to increase risk for later psychotic illness in genetically vulnerable individuals, with magnitude of risk increasing with frequency, potency, and earlier age of onset. The adolescent endocannabinoid system is involved in synaptic pruning and cortical maturation, and chronic disruption appears to leave lasting effects.
Hold the principle. The endocannabinoid system flows backward. It is a master feedback brake. Its receptors are everywhere. When you perturb it pharmacologically, the effects are diffuse — for better and for worse.